Overview of main clinical studies for MASLD/MASH with GLP-1 receptor agonists and dual or triple agonists targeting glucagon/GIP/GLP-1 receptors Liraglutide Liraglutide, a once-daily GLP-1 receptor agonist with authorized indications for type 2 diabetes and obesity, was evaluated in the LEAN trial (NCT01237119), a phase 2 randomized controlled study enrolling 52 adults with biopsy-proven MASH [22]
Research for new antischistosome drugs is limited by the difficulty of working with the parasite and the low priority the pharmaceutical industry generally places on tropical diseases
522,523 Overall, biologics and monoclonal antibody-related drugs have played important roles in the treatment of ulcerative colitis, providing new therapeutic options for many patients
Response times are typically prompt, with most inquiries receiving responses within 24 hours
Las modificaciones dietticas estratgicas pueden mitigar significativamente los problemas intestinales asociados con los medicamentos GLP-1, mejorando tanto la tolerabilidad como la efectividad del tratamiento
.png)
.png)
